Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Larotrectinib is an orally administered inhibitor of the TRK kinase and is highly selective only for the TRK family of receptors(IC50s = 2-20 nM).
Description | Larotrectinib is an orally administered inhibitor of the TRK kinase and is highly selective only for the TRK family of receptors(IC50s = 2-20 nM). |
Targets&IC50 | TRK:2-20 nM |
In vivo | In vivo, Larotrectinib?(60 and 200 mg/kg) reduces tumor growth in a KM12 mouse xenograft model[1]. |
Animal Research | Mice were maintained under aseptic conditions.?The care and treatment of experimental animals was in accordance with institutional guidelines.?5 × 10^5 KM12 cells were injected subcutaneously into the dorsal flank area of the mice.?Tumor volume was monitored by direct measurement with calipers and calculated by the formula: length × (width^2)/2.?Following the establishment of tumor and when the tumor size was between 150–200 mm^2, mice were randomly selected to receive diluent, 60 mg/kg/dose or 200 mg/kg/dose of Larotrectinib(LOXO-101).?LOXO-101 was administered by oral gavage once daily for 14 days.?After the last dose, tissue and blood were collected at 3, 6 and 24 hours post-treatment[1]. |
Synonyms | LOXO-101, ARRY-470 |
Molecular Weight | 428.44 |
Formula | C21H22F2N6O2 |
CAS No. | 1223403-58-4 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 4.6 mg/mL (10.74 mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Larotrectinib 1223403-58-4 Apoptosis Tyrosine Kinase/Adaptors Trk receptor Trk Receptor LOXO101 inhibit LOXO 101 Inhibitor Tropomyosin related kinase receptor ARRY470 LOXO-101 ARRY-470 ARRY 470 inhibitor